A pair of drugmakers priced their initial public offerings on Thursday, delivering the best month for US health care ...

Drug developer Maze Therapeutics said on Monday it was targeting a valuation of up to $728.1 million in its New York initial ...

Shares of Maze Therapeutics rose nearly 1% in their Nasdaq debut on Friday, valuing the kidney disease drug developer at $690.37 million.

Non-resident property transactions in India face compliance challenges, including obtaining TAN, depositing TDS, and filing e ...

Metsera and Maze Therapeutics have become the second and third biotechs to complete an initial public offering (IPO) on the ...

An international team of scientists have discovered that soap could be important to helping our understanding of complex ...

Maze Therapeutics has set out plans for a $131 million IPO as the company prepares to start dosing its lead kidney drug in a ...

Until this year, the Guinness World Record was held by a nearly 13,000-square-foot ice labyrinth in New York that took the ...

Maze Therapeutics, Inc MAZE IPO will take place January, 31 on the NASDAQ exchange under the ticker MAZE. The company is offering shares at an expected price between $15.00 and $17.00 per share with ...

The casual-dining chain’s 31% same-store sales number was shocking by any standard, and stands up to some of the best ...

An anonymous coder, writing to 404media under the fake name Aaron B, has also been feeling the malaise, and he's doing ...

All Points North explores why foreign nationals may face job discrimination in Finland and looks at measures to improve ...